ERBB2 and breast cancer: Likewise, the basal-like and HER2-enriched breast cancer patients also were in the high-risk group, which is consistent with the clinical findings [31] that HER2-enriched and lumB subtypes of breast cancer have a poor prognosis compared with the lumA and normal-like breast cancers.